Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
- PMID: 36652354
- DOI: 10.1056/NEJMoa2206834
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
Abstract
Background: Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis. Futibatinib, a next-generation, covalently binding FGFR1-4 inhibitor, has been shown to have both antitumor activity in patients with FGFR-altered tumors and strong preclinical activity against acquired resistance mutations associated with ATP-competitive FGFR inhibitors.
Methods: In this multinational, open-label, single-group, phase 2 study, we enrolled patients with unresectable or metastatic FGFR2 fusion-positive or FGFR2 rearrangement-positive intrahepatic cholangiocarcinoma and disease progression after one or more previous lines of systemic therapy (excluding FGFR inhibitors). The patients received oral futibatinib at a dose of 20 mg once daily in a continuous regimen. The primary end point was objective response (partial or complete response), as assessed by independent central review. Secondary end points included the response duration, progression-free and overall survival, safety, and patient-reported outcomes.
Results: Between April 16, 2018, and November 29, 2019, a total of 103 patients were enrolled and received futibatinib. A total of 43 of 103 patients (42%; 95% confidence interval, 32 to 52) had a response, and the median duration of response was 9.7 months. Responses were consistent across patient subgroups, including patients with heavily pretreated disease, older adults, and patients who had co-occurring TP53 mutations. At a median follow-up of 17.1 months, the median progression-free survival was 9.0 months and overall survival was 21.7 months. Common treatment-related grade 3 adverse events were hyperphosphatemia (in 30% of the patients), an increased aspartate aminotransferase level (in 7%), stomatitis (in 6%), and fatigue (in 6%). Treatment-related adverse events led to permanent discontinuation of futibatinib in 2% of the patients. No treatment-related deaths occurred. Quality of life was maintained throughout treatment.
Conclusions: In previously treated patients with FGFR2 fusion or rearrangement-positive intrahepatic cholangiocarcinoma, the use of futibatinib, a covalent FGFR inhibitor, led to measurable clinical benefit. (Funded by Taiho Oncology and Taiho Pharmaceutical; FOENIX-CCA2 ClinicalTrials.gov number, NCT02052778.).
Copyright © 2023 Massachusetts Medical Society.
Comment in
-
The role of FGFR inhibitors in the treatment of intrahepatic cholangiocarcinoma-unveiling the future challenges in drug therapy.Hepatobiliary Surg Nutr. 2023 Oct 1;12(5):790-794. doi: 10.21037/hbsn-23-411. Epub 2023 Sep 15. Hepatobiliary Surg Nutr. 2023. PMID: 37886210 Free PMC article. No abstract available.
-
Futibatinib: new targeted therapy in intrahepatic cholangiocarcinoma.Hepatobiliary Surg Nutr. 2023 Dec 1;12(6):923-926. doi: 10.21037/hbsn-23-476. Epub 2023 Nov 15. Hepatobiliary Surg Nutr. 2023. PMID: 38115933 Free PMC article. No abstract available.
Similar articles
-
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.J Hepatol. 2024 Feb;80(2):322-334. doi: 10.1016/j.jhep.2023.10.041. Epub 2023 Nov 14. J Hepatol. 2024. PMID: 37972659
-
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28. J Clin Oncol. 2018. PMID: 29182496 Free PMC article. Clinical Trial.
-
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.Oncologist. 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. Oncologist. 2023. PMID: 37390492 Free PMC article. Review.
-
Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.Clin Cancer Res. 2024 Jan 5;30(1):198-208. doi: 10.1158/1078-0432.CCR-23-1317. Clin Cancer Res. 2024. PMID: 37843855 Free PMC article.
-
Futibatinib: First Approval.Drugs. 2022 Dec;82(18):1737-1743. doi: 10.1007/s40265-022-01806-z. Drugs. 2022. PMID: 36441501 Review.
Cited by
-
Response of FGFR-2 Positive Adenoid Cystic Carcinoma to Futibatinib: A Case Report.Cureus. 2024 Jun 27;16(6):e63332. doi: 10.7759/cureus.63332. eCollection 2024 Jun. Cureus. 2024. PMID: 39077220 Free PMC article.
-
Role of molecular biology in the management of pancreatic cancer.World J Gastrointest Oncol. 2024 Jul 15;16(7):2902-2914. doi: 10.4251/wjgo.v16.i7.2902. World J Gastrointest Oncol. 2024. PMID: 39072173 Free PMC article. Review.
-
Integrating Molecular Insights into Biliary Tract Cancer Management: A Review of Personalized Therapeutic Strategies.Curr Oncol. 2024 Jun 21;31(7):3615-3629. doi: 10.3390/curroncol31070266. Curr Oncol. 2024. PMID: 39057138 Free PMC article. Review.
-
Fibroblast growth factor receptor signaling in estrogen receptor-positive breast cancer: mechanisms and role in endocrine resistance.Front Oncol. 2024 Jul 8;14:1406951. doi: 10.3389/fonc.2024.1406951. eCollection 2024. Front Oncol. 2024. PMID: 39040443 Free PMC article. Review.
-
Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP.J Pathol Transl Med. 2024 Jul;58(4):147-164. doi: 10.4132/jptm.2023.11.01. Epub 2024 Jan 10. J Pathol Transl Med. 2024. PMID: 39026440 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous